Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 391,103
  • Shares Outstanding, K 267,879
  • Annual Sales, $ 236,200 K
  • Annual Income, $ -5,350 K
  • EBIT $ 24 M
  • EBITDA $ 25 M
  • 60-Month Beta 0.39
  • Price/Sales 1.66
  • Price/Cash Flow N/A
  • Price/Book 11.88

Options Overview Details

View History
  • Implied Volatility 102.23% (-18.39%)
  • Historical Volatility 74.30%
  • IV Percentile 35%
  • IV Rank 11.49%
  • IV High 442.51% on 02/19/26
  • IV Low 58.06% on 05/14/25
  • Expected Move (DTE 4) 0.1700 (11.64%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 878
  • Volume Avg (30-Day) 423
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 35,751
  • Open Int (30-Day) 33,101
  • Expected Range 1.2900 to 1.6300

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.01
  • Number of Estimates 3
  • High Estimate 0.01
  • Low Estimate -0.03
  • Prior Year 0.03
  • Growth Rate Est. (year over year) -133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1400 +28.07%
on 02/20/26
1.5200 -3.95%
on 03/13/26
+0.2500 (+20.66%)
since 02/13/26
3-Month
1.1400 +28.07%
on 02/20/26
1.7300 -15.61%
on 12/22/25
-0.2000 (-12.05%)
since 12/12/25
52-Week
1.1400 +28.07%
on 02/20/26
4.0787 -64.20%
on 07/11/25
-0.2300 (-13.61%)
since 03/13/25

Most Recent Stories

More News
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.4600 (+4.29%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.4600 (+4.29%)
Akebia Therapeutics: Q4 Earnings Snapshot

Akebia Therapeutics: Q4 Earnings Snapshot

AKBA : 1.4600 (+4.29%)
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

Q4 2025 net product revenues of  $54.3 million ; 2025 full-year net product revenues of $227.3 million , representing a 49% increase over 2024 full-year net product revenues Expect significant...

AKBA : 1.4600 (+4.29%)
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December...

AKBA : 1.4600 (+4.29%)
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.4600 (+4.29%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.4600 (+4.29%)
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

 Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental...

AKBA : 1.4600 (+4.29%)
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.4600 (+4.29%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.4600 (+4.29%)

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 1.6399
2nd Resistance Point 1.5799
1st Resistance Point 1.5200
Last Price 1.4600
1st Support Level 1.4001
2nd Support Level 1.3401
3rd Support Level 1.2802

See More

52-Week High 4.0787
Fibonacci 61.8% 2.9561
Fibonacci 50% 2.6093
Fibonacci 38.2% 2.2626
Last Price 1.4600
52-Week Low 1.1400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar